logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5529.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5529.produseast1
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19 | Collections | MSF Science Portal
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

Collection Content

Journal Article
|
Research

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan

Mesic A, Ishaq S, Khan WH, Mureed A, Mar HT,  et al.
2022-01-03 • Tropical Medicine and International Health
2022-01-03 • Tropical Medicine and International Health
OBJECTIVES
To describe the effect of adaptations to a person-centred care with short oral regimens on retention in care for rifampicin-resistant TB (RR-TB) in Kandahar province, Afgh...
Journal Article
|
Letter

Urine LAM diagnostics can close the deadly testing gap for TB

Deborggraeve S, Menghaney L, Lynch S, McKenna L, Branigan D
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Letter

TB research requires strong protections, innovation, and increased funding in response to COVID-19

Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
Conference Material
|
Abstract

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Nyang'wa BT, Berry C, Motta I, Kazounis E
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...
Conference Material
|
Video

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Berry C
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Journal Article
|
Letter

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients

Mohr-Holland E, Daniels J, Douglas-Jones B, Mema N, Scott V,  et al.
2021-05-01 • International Journal of Tuberculosis and Lung Disease
2021-05-01 • International Journal of Tuberculosis and Lung Disease
Journal Blog
|
Perspective

The TB community in 2021—tired, frustrated, but hopeful

Berry C
2021-03-24 • BMJ Opinion (blog)
2021-03-24 • BMJ Opinion (blog)
The TB community continues to tackle one of the world’s oldest epidemics while struggling with the newest one, writes Catherine Berry
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

See more collections

Covid-19 in humanitarian settings—modelling, measuring & applying lessons (MSF Scientific Days International 2022)
Covid-19 in humanitarian settings—modelling, measuring & appl...
No description available
World NTD Day
World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

MSF Scientific Days International 2024
MSF Scientific Days International 2024
On 16 May people from within and outside MSF will gather in London, joined by online participants from over 100 countries, for this annual ‘conference without borders’ showcasing medical research from fragile and conflict affected settings. All too often the populations MSF and others work with are excluded from the benefits of research. Yet they are the ones that often need these benefits most. So speakers will consider how MSF’s research has impacted the way our projects deliver care, how knowledge gaps can be pivotal to political gatekeeping and to triggering appropriate humanitarian responses, and how identifying best practices and funding innovation are key to improving our capacity to act. Here you can view abstracts for all scientific presentations, which focus on infectious diseases, outbreaks, vaccination, and mortality.
View All Collections